Tags

Type your tag names separated by a space and hit enter

Dopaminergic mechanisms controlling urethral function in rats.
Neurourol Urodyn. 2006; 25(5):480-9.NU

Abstract

AIMS

To investigate the role of dopamine receptor subtypes in the control of urethral activity.

METHODS

Simultaneous recordings of intravesical and urethral perfusion pressure (UPP) were performed in rats under urethane anesthesia. Changes in coordinated activity of the bladder and urethral sphincter were examined following intravenous (i.v.), intrathecal (i.t.), or intracerebroventricular (i.c.v.) administration of dopamine D1- and D2-like receptor agonists (SKF38393 and quinpirole, respectively) and antagonists (SCH23390 and remoxipride, respectively).

RESULTS

Quinpirole (0.03, 0.1, and 0.3 mg/kg i.v.) dose-dependently decreased baseline urethral pressure to 45.33 +/- 5.8, 33.7 +/- 3.3 (P < 0.05, n = 6), and 27.7 +/- 3.3 cm H(2)O (P < 0.05, n = 5) from the control value (46.0 +/- 4.0 cm H(2)O), respectively. i.c.v. injection of quinpirole (1 microg) decreased baseline urethral pressure to 33.6 +/- 5.0 cm H(2)O (P < 0.05, n = 4) from the control value (51.4 +/- 4.9 cm H(2)O) in contrast to the insignificant effects of i.t. administration of the drug (3 microg). The decrement of baseline pressure induced by quinpirole (0.1 mg/kg i.v.) was suppressed by alpha-bungarotoxin (BGT), a neuromuscular blocking agent. SCH23390 (1 and 3 mg/kg, i.v.) dose-dependently decreased the frequency of high frequency oscillation (HFO) of the urethral sphincter. SKF38393 or remoxipride did not have significant effects on any parameters of bladder and urethral activity.

CONCLUSIONS

These results indicate that activation of D2-like dopamine receptors at a supraspinal site can suppress activity of the striated muscle urethral sphincter. Thus, decreased urethral resistance induced by D2 dopamine receptor activation might aggravate urge incontinence symptoms often seen in patients with Parkinson's disease (PD).

Authors+Show Affiliations

Department of Urology, University of Pittsburgh, Pittsburgh, Pennsylvania 15213, USA.No affiliation info availableNo affiliation info availableNo affiliation info availableNo affiliation info availableNo affiliation info availableNo affiliation info availableNo affiliation info availableNo affiliation info available

Pub Type(s)

Journal Article
Research Support, N.I.H., Extramural

Language

eng

PubMed ID

16721842

Citation

Ogawa, Teruyuki, et al. "Dopaminergic Mechanisms Controlling Urethral Function in Rats." Neurourology and Urodynamics, vol. 25, no. 5, 2006, pp. 480-9.
Ogawa T, Seki S, Masuda H, et al. Dopaminergic mechanisms controlling urethral function in rats. Neurourol Urodyn. 2006;25(5):480-9.
Ogawa, T., Seki, S., Masuda, H., Igawa, Y., Nishizawa, O., Kuno, S., Chancellor, M. B., de Groat, W. C., & Yoshimura, N. (2006). Dopaminergic mechanisms controlling urethral function in rats. Neurourology and Urodynamics, 25(5), 480-9.
Ogawa T, et al. Dopaminergic Mechanisms Controlling Urethral Function in Rats. Neurourol Urodyn. 2006;25(5):480-9. PubMed PMID: 16721842.
* Article titles in AMA citation format should be in sentence-case
TY - JOUR T1 - Dopaminergic mechanisms controlling urethral function in rats. AU - Ogawa,Teruyuki, AU - Seki,Satoshi, AU - Masuda,Hitoshi, AU - Igawa,Yasuhiko, AU - Nishizawa,Osamu, AU - Kuno,Sadako, AU - Chancellor,Michael B, AU - de Groat,William C, AU - Yoshimura,Naoki, PY - 2006/5/25/pubmed PY - 2006/10/13/medline PY - 2006/5/25/entrez SP - 480 EP - 9 JF - Neurourology and urodynamics JO - Neurourol Urodyn VL - 25 IS - 5 N2 - AIMS: To investigate the role of dopamine receptor subtypes in the control of urethral activity. METHODS: Simultaneous recordings of intravesical and urethral perfusion pressure (UPP) were performed in rats under urethane anesthesia. Changes in coordinated activity of the bladder and urethral sphincter were examined following intravenous (i.v.), intrathecal (i.t.), or intracerebroventricular (i.c.v.) administration of dopamine D1- and D2-like receptor agonists (SKF38393 and quinpirole, respectively) and antagonists (SCH23390 and remoxipride, respectively). RESULTS: Quinpirole (0.03, 0.1, and 0.3 mg/kg i.v.) dose-dependently decreased baseline urethral pressure to 45.33 +/- 5.8, 33.7 +/- 3.3 (P < 0.05, n = 6), and 27.7 +/- 3.3 cm H(2)O (P < 0.05, n = 5) from the control value (46.0 +/- 4.0 cm H(2)O), respectively. i.c.v. injection of quinpirole (1 microg) decreased baseline urethral pressure to 33.6 +/- 5.0 cm H(2)O (P < 0.05, n = 4) from the control value (51.4 +/- 4.9 cm H(2)O) in contrast to the insignificant effects of i.t. administration of the drug (3 microg). The decrement of baseline pressure induced by quinpirole (0.1 mg/kg i.v.) was suppressed by alpha-bungarotoxin (BGT), a neuromuscular blocking agent. SCH23390 (1 and 3 mg/kg, i.v.) dose-dependently decreased the frequency of high frequency oscillation (HFO) of the urethral sphincter. SKF38393 or remoxipride did not have significant effects on any parameters of bladder and urethral activity. CONCLUSIONS: These results indicate that activation of D2-like dopamine receptors at a supraspinal site can suppress activity of the striated muscle urethral sphincter. Thus, decreased urethral resistance induced by D2 dopamine receptor activation might aggravate urge incontinence symptoms often seen in patients with Parkinson's disease (PD). SN - 0733-2467 UR - https://www.unboundmedicine.com/medline/citation/16721842/Dopaminergic_mechanisms_controlling_urethral_function_in_rats_ L2 - https://doi.org/10.1002/nau.20260 DB - PRIME DP - Unbound Medicine ER -